Development of a New Class of Pharmacological Mediators for Myeloperoxidase Inhib

描述（由申请人提供）：心血管疾病是指涉及心脏或血管的疾病，特别是与动脉粥样硬化（动脉疾病）有关的疾病。这种疾病是世界上的头号杀手，尤其是在美国。髓过氧化物酶（MPO）与许多心血管疾病有关，迄今为止还没有单一的药物可用于治疗。抗髓过氧化物酶（MPO）的新候选药物的开发可能有助于预防易损动脉粥样硬化斑块的进展。我们建议开发一类新的基于自然可用化学结构的髓过氧化物酶抑制药理介质。我们的初步研究通过体外模型评估了两种特异性MPO抑制剂的疗效。所提出的抑制剂的显著特征是这些抑制剂对MPO具有特异性以及它们的通用抗氧化性能。可行性研究的具体目标如下：

DESCRIPTION (provided by applicant): Cardiovascular disease refers to the class of diseases that involve the heart or blood vessels especially those related to atherosclerosis (arterial disease). This disease is the number one killer around the world, particularly in the United States. Myeloperoxidase (MPO) enzyme has been implicated in many cardiovascular diseases and to date there is no single drug available for treatment. The development of new drug candidates against myeloperoxidase (MPO) may prove to be useful in the prevention of the progression of vulnerable atherosclerotic plaque. We propose the development of a new class of pharmacological mediators for myeloperoxidase inhibition based on naturally available chemical structures. Our preliminary studies identified two specific MPO inhibitors by evaluating their efficacy using in vitro model. The salient features of the proposed inhibitors are that these inhibitors are specific toward MPO as well as their generic anti oxidant properties. The feasibility study has specific aims as listed below: